Operaciones Morphosys AG - MOR CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.09 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024161% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.020283% | ||||||||
Horario tarifa nocturna | 22:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | EUR | ||||||||
Margen | 20% | ||||||||
Mercado de valores | Germany | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
MorphoSys AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Cierre previo* | 19.23 |
Abrir* | 19 |
Cambio de 1 año* | -31.56% |
Rango del día* | 18.5 - 19 |
Rango de 52 semanas | 11.81-28.31 |
Volumen medio (10 días) | 108.88K |
Volumen medio (3 meses) | 7.20M |
Capitalización de mercado | 650.41M |
Ratio P/E | -100.00K |
Acciones en circulación | 34.16M |
Ingresos | 249.61M |
EPS | -25.23 |
Dividendo (Rendimiento %) | N/A |
Beta | 0.73 |
Próxima fecha de resultados | Mar 15, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 18.87 | -0.42 | -2.18% | 19.29 | 19.29 | 18.26 |
Feb 2, 2023 | 19.23 | 0.56 | 3.00% | 18.67 | 19.71 | 18.53 |
Feb 1, 2023 | 18.43 | 0.26 | 1.43% | 18.17 | 18.73 | 18.14 |
Jan 31, 2023 | 17.96 | 0.25 | 1.41% | 17.71 | 18.27 | 17.33 |
Jan 30, 2023 | 17.96 | 0.09 | 0.50% | 17.87 | 18.22 | 17.75 |
Jan 27, 2023 | 18.06 | 0.18 | 1.01% | 17.88 | 18.27 | 17.83 |
Jan 26, 2023 | 17.96 | 0.14 | 0.79% | 17.82 | 18.18 | 17.70 |
Jan 25, 2023 | 17.73 | 0.67 | 3.93% | 17.06 | 17.79 | 16.87 |
Jan 24, 2023 | 17.00 | -0.45 | -2.58% | 17.45 | 17.69 | 16.88 |
Jan 23, 2023 | 17.47 | 0.23 | 1.33% | 17.24 | 17.73 | 16.87 |
Jan 20, 2023 | 16.94 | 0.70 | 4.31% | 16.24 | 17.23 | 16.05 |
Jan 19, 2023 | 16.30 | -0.58 | -3.44% | 16.88 | 17.11 | 15.33 |
Jan 18, 2023 | 17.04 | 0.19 | 1.13% | 16.85 | 17.27 | 16.57 |
Jan 17, 2023 | 16.97 | 0.69 | 4.24% | 16.28 | 17.01 | 16.13 |
Jan 16, 2023 | 16.47 | -0.07 | -0.42% | 16.54 | 16.82 | 16.17 |
Jan 13, 2023 | 16.42 | 1.14 | 7.46% | 15.28 | 16.80 | 15.14 |
Jan 12, 2023 | 15.12 | -0.38 | -2.45% | 15.50 | 15.68 | 14.89 |
Jan 11, 2023 | 15.06 | 0.14 | 0.94% | 14.92 | 15.13 | 14.45 |
Jan 10, 2023 | 14.63 | 0.38 | 2.67% | 14.25 | 14.94 | 14.14 |
Jan 9, 2023 | 14.36 | 0.46 | 3.31% | 13.90 | 14.47 | 13.82 |
Morphosys AG Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos totales | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
Ingresos | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
Gastos totales de explotación | 109.685 | 134.398 | 136.584 | 178.803 | 301.039 | 685.818 |
Gastos de venta/general/administración Gastos, total | 12.7561 | 15.7687 | 26.2302 | 55.7672 | 152.193 | 188.958 |
Investigación y desarrollo | 82.1921 | 103.315 | 83.988 | 103.861 | 120.489 | 219.072 |
Depreciation / Amortization | 3.764 | 4.03 | 3.75 | 3.458 | 7.255 | 7.557 |
Gasto (ingreso) por intereses - Explotación neta | 0.208 | 0.359 | -0.22 | 0.18 | -18.237 | -13.584 |
Gastos (ingresos) extraordinarios | 10.141 | 9.864 | 20.224 | 9.462 | 6.795 | 231.949 |
Other Operating Expenses, Total | 0.62335 | 1.06219 | 0.81471 | 2.67494 | 13.4374 | 19.6719 |
Ingresos de explotación | -59.941 | -67.6077 | -60.1411 | -107.048 | 26.6592 | -506.207 |
Ingresos por intereses (gastos), netos No operativos | 0.132 | -0.768 | -0.237 | 1.354 | -35.614 | -81.632 |
Otros, netos | -0.05516 | -0.41446 | -0.0987 | -0.8269 | 31.4468 | -3.21234 |
Ingresos netos antes de impuestos | -59.8642 | -68.7901 | -60.4768 | -106.52 | 22.492 | -591.051 |
Ingresos netos después de impuestos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Beneficio neto antes de partidas extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Ingresos netos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Ajuste por dilución | 0 | |||||
Beneficio neto diluido | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Promedio ponderado de acciones diluidas | 26.4434 | 28.9476 | 31.3389 | 31.6112 | 33.1679 | 33.4011 |
BPA diluido sin partidas extraordinarias | -2.28347 | -2.41217 | -1.79241 | -3.25879 | 2.95137 | -15.4025 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 | 0 |
BPA normalizado diluido | -2.0342 | -2.19068 | -1.20385 | -3.04945 | 3.20838 | -10.8879 |
Coste de los ingresos, total | 1.79663 | 3.4002 | 19.1071 | 32.1947 | ||
Beneficio bruto | 74.6459 | 68.3551 | 308.591 | 147.417 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Ingresos totales | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
Ingresos | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
Coste de los ingresos, total | 5.04798 | 10.1363 | 7.48222 | 9.52819 | 7.89249 |
Beneficio bruto | 42.1416 | 28.0977 | 33.7625 | 43.4153 | 33.574 |
Gastos totales de explotación | 76.4968 | 109.175 | 122.582 | 376.565 | 111.856 |
Gastos de venta/general/administración Gastos, total | 38.4237 | 40.1544 | 51.347 | 50.7098 | 36.4825 |
Investigación y desarrollo | 32.3171 | 40.5068 | 62.6749 | 87.0124 | 65.048 |
Gasto (ingreso) por intereses - Explotación neta | -1.1 | 1.6 | -1.7 | -3.24 | |
Gastos (ingresos) extraordinarios | -0.089 | 18.604 | 0.135 | 230.949 | 0.089 |
Other Operating Expenses, Total | 1.89697 | -1.8263 | 0.94256 | 1.60571 | 2.34434 |
Ingresos de explotación | -29.3072 | -70.9412 | -81.3369 | -323.621 | -70.3899 |
Ingresos por intereses (gastos), netos No operativos | 7.1 | -7.7 | 4.2 | -95.782 | 3.4 |
Otros, netos | -33.8928 | 113.038 | -76.8684 | 4.06089 | -55.6612 |
Ingresos netos antes de impuestos | -56.0999 | 34.3967 | -154.005 | -415.342 | -122.651 |
Ingresos netos después de impuestos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Beneficio neto antes de partidas extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Ingresos netos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Beneficio neto diluido | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Promedio ponderado de acciones diluidas | 32.7586 | 35.3712 | 34.1332 | 34.1487 | 34.1488 |
BPA diluido sin partidas extraordinarias | -1.27015 | 0.59071 | -3.30388 | -11.1563 | -3.59167 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
BPA normalizado diluido | -1.27191 | 1.20559 | -3.30892 | -6.76036 | -3.58906 |
Depreciation / Amortization | 1.7 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Activo Corriente | 308.056 | 340.681 | 388.905 | 303.693 | 1206.82 | 1132.97 |
Efectivo e inversiones a corto plazo | 145.074 | 164.26 | 358.964 | 272.504 | 1090.32 | 993.664 |
Cash | 73.929 | 76.589 | 45.4598 | 44.314 | 109.795 | 123.248 |
Efectivo y Equivalentes | 1.25166 | 1.13313 | ||||
Inversiones a corto plazo | 69.8938 | 86.5382 | 313.504 | 228.19 | 980.522 | 870.416 |
Total deudores, neto | 149.682 | 163.833 | 20.7414 | 20.3408 | 89.8356 | 85.79 |
Accounts Receivable - Trade, Net | 12.5967 | 11.2343 | 17.7329 | 15.0817 | 83.3543 | 75.911 |
Total Inventory | 0.31037 | 0.30075 | 0.24516 | 0.28821 | 9.96266 | 20.7552 |
Prepaid Expenses | 3.5 | 2.1 | 3.6 | 5.8 | 6.698 | 16.815 |
Other Current Assets, Total | 9.48947 | 10.1868 | 5.35488 | 4.75963 | 10.0035 | 15.9454 |
Total Assets | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
Property/Plant/Equipment, Total - Net | 4.18911 | 3.52635 | 3.53071 | 47.8131 | 50.7415 | 49.5921 |
Property/Plant/Equipment, Total - Gross | 19.047 | 19.836 | 18.597 | 63.9362 | 68.4008 | 69.8613 |
Accumulated Depreciation, Total | -14.858 | -16.31 | -15.066 | -16.123 | -17.659 | -20.269 |
Goodwill, Net | 7.3648 | 7.3648 | 3.67623 | 3.67623 | 1.61923 | 335.574 |
Intangibles, Net | 60.5745 | 60.4821 | 43.6888 | 41.1221 | 69.3752 | 838.322 |
Note Receivable - Long Term | 79.5212 | 0 | ||||
Other Long Term Assets, Total | 3.89409 | 3.34429 | 2.98172 | 1.13603 | 134.373 | 199.796 |
Total Current Liabilities | 38.3019 | 47.701 | 45.9233 | 61.5579 | 200.459 | 284.538 |
Accounts Payable | 8.636 | 4.818 | 7.399 | 11.012 | 47.818 | 73.787 |
Accrued Expenses | 22.838 | 36.408 | 36.53 | 44.971 | 79.2 | 113.055 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 6.82795 | 6.47504 | 1.99429 | 3.04744 | 69.9627 | 94.0353 |
Total Liabilities | 48.1399 | 56.7272 | 50.3911 | 101.738 | 1038.19 | 2311.38 |
Total Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 40.0416 | 314.724 | 322.13 |
Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 0 | 272.76 | 282.785 |
Deferred Income Tax | 7.42184 | 7.81126 | 3.50723 | 0 | 5.05747 | 22.0654 |
Other Liabilities, Total | 2.19788 | 1.12709 | 0.88908 | 0.13809 | 517.951 | 1682.64 |
Total Equity | 415.46 | 358.671 | 488.373 | 394.702 | 621.322 | 244.876 |
Common Stock | 29.1598 | 29.4208 | 31.8396 | 31.958 | 32.89 | 34.2319 |
Additional Paid-In Capital | 428.361 | 438.558 | 619.908 | 628.177 | 748.979 | 833.321 |
Retained Earnings (Accumulated Deficit) | -27.5487 | -97.3751 | -152.766 | -255.78 | -157.889 | -672.349 |
Treasury Stock - Common | -14.6482 | -11.827 | -10.3988 | -8.35725 | -4.86874 | -3.08505 |
Unrealized Gain (Loss) | 0.1361 | -0.10548 | 0 | |||
Total Liabilities & Shareholders’ Equity | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
Total Common Shares Outstanding | 28.7638 | 29.1011 | 31.5585 | 31.7322 | 32.7586 | 34.1488 |
Long Term Investments | 95.9811 | 98.999 | 196.588 | 0 | ||
Other Equity, Total | -0.21089 | -1.29572 | 2.21142 | 52.7576 | ||
Current Port. of LT Debt/Capital Leases | 2.52742 | 3.47855 | 3.66106 | |||
Capital Lease Obligations | 40.0416 | 41.9638 | 39.3458 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 1257.38 | 1255.91 | 1294.76 | 1132.97 | 1013.44 |
Efectivo e inversiones a corto plazo | 1122.26 | 1095.34 | 1155.19 | 993.664 | 855.47 |
Cash | 109.586 | 297.335 | 249.767 | 123.248 | 108.873 |
Inversiones a corto plazo | 1012.67 | 798.01 | 905.426 | 870.416 | 746.597 |
Total deudores, neto | 104.173 | 108.192 | 82.0685 | 79.227 | 80.0492 |
Accounts Receivable - Trade, Net | 101.298 | 97.1665 | 77.044 | 75.911 | 74.0944 |
Total Inventory | 13.4 | 14.5171 | 13.2692 | 20.7552 | 20.89 |
Prepaid Expenses | 17.5465 | 37.8531 | 44.2278 | 39.3234 | 57.0263 |
Total Assets | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
Property/Plant/Equipment, Total - Net | 49.9224 | 49.4239 | 51.9162 | 49.5921 | 48.6483 |
Goodwill, Net | 1.61923 | 1.61923 | 570.959 | 335.574 | 342.343 |
Intangibles, Net | 69.0447 | 79.0253 | 787.906 | 838.322 | 853.209 |
Long Term Investments | 125.713 | 55.3782 | 0 | 0 | |
Other Long Term Assets, Total | 146.23 | 136.061 | 178.404 | 199.796 | 199.721 |
Total Current Liabilities | 202.263 | 204.554 | 259.123 | 284.538 | 238.959 |
Payable/Accrued | 124.297 | 134.663 | 168.399 | 188.077 | 145.55 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.02894 | 3.68179 | 4.09169 | 3.66106 | 5.31028 |
Other Current Liabilities, Total | 73.9369 | 66.2085 | 86.6328 | 92.8001 | 88.0983 |
Total Liabilities | 1070.25 | 976.007 | 2286.69 | 2311.38 | 2315.62 |
Total Long Term Debt | 316.63 | 318.27 | 320.184 | 322.13 | 322.835 |
Long Term Debt | 275.193 | 277.677 | 280.218 | 282.785 | 284.218 |
Capital Lease Obligations | 41.4369 | 40.5935 | 39.9657 | 39.3458 | 38.6175 |
Deferred Income Tax | 2.32821 | 5.05747 | 23.8584 | 22.0654 | 22.5267 |
Other Liabilities, Total | 549.032 | 448.126 | 1683.53 | 1682.64 | 1731.3 |
Total Equity | 579.653 | 601.407 | 597.25 | 244.876 | 141.739 |
Common Stock | 32.89 | 32.8925 | 34.2319 | 34.2319 | 34.2319 |
Additional Paid-In Capital | 749.846 | 749.284 | 832.584 | 833.321 | 833.376 |
Retained Earnings (Accumulated Deficit) | -199.497 | -178.603 | -291.375 | -672.349 | -795 |
Treasury Stock - Common | -4.86874 | -3.78304 | -3.37201 | -3.08505 | -3.08505 |
Other Equity, Total | 1.2836 | 1.61683 | 25.1808 | 52.7576 | 72.2164 |
Total Liabilities & Shareholders’ Equity | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
Total Common Shares Outstanding | 32.7586 | 32.7905 | 34.141 | 34.1488 | 34.1488 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos netos/Línea de salida | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Efectivo de actividades de explotación | -46.6157 | -38.4459 | -32.7813 | -81.0702 | 34.5197 | -481.445 |
Efectivo de actividades de explotación | 3.76381 | 4.02895 | 3.75026 | 6.24516 | 8.32956 | 10.091 |
Partidas no monetarias | -4.4191 | -3.29514 | 24.182 | -2.07177 | -83.4769 | 200.528 |
Cash Taxes Paid | 0.54038 | 1.86198 | 0.03384 | 0.06256 | 0.30397 | 64.6096 |
Intereses pagados en efectivo | 0.00182 | 0 | 0.13427 | 1.01132 | 1.43149 | 4.74485 |
Cambios en el capital circulante | 14.4224 | 30.6468 | -4.54142 | 17.7704 | 11.7764 | -177.604 |
Efectivo de actividades de inversión | -80.786 | 32.9325 | -177.751 | 79.4841 | -879.623 | -831.01 |
Gastos de capital | -2.91349 | -13.1489 | -2.46532 | -3.66564 | -49.3365 | -26.1562 |
Otras partidas de flujo de caja de inversión, total | -77.8726 | 46.0813 | -175.285 | 83.1497 | -830.286 | -804.854 |
Efectivo procedente de actividades de financiación | 110.403 | 8.17382 | 179.462 | 0.35324 | 907.186 | 1322.92 |
Elementos de flujo de caja de financiación | -2.78047 | -0.01553 | -15.1726 | -1.01132 | 508.655 | 1241.08 |
Emisión (retiro) de acciones, neto | 113.19 | 0 | 193.614 | 0 | 80.5985 | 84.73 |
Emisión (amortización) de deuda, neta | -0.00671 | 8.18935 | 1.02085 | 1.36456 | 317.933 | -2.88511 |
Efectos del cambio de divisas | 0 | -0.05946 | 0.08712 | 3.39766 | 2.98531 | |
Variación neta de la tesorería | -16.999 | 2.66047 | -31.1293 | -1.14579 | 65.4806 | 13.4536 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -41.6082 | -20.714 | -133.486 | -514.46 | -122.651 |
Cash From Operating Activities | -42.2207 | -131.585 | -323.96 | -481.445 | -143.812 |
Cash From Operating Activities | 2.31626 | 4.65405 | 7.3535 | 10.091 | 2.57174 |
Non-Cash Items | 16.223 | -79.0437 | -68.6942 | 200.528 | 36.1088 |
Cash Taxes Paid | 0.07992 | 0.08336 | 1.31085 | 64.6096 | 0.07782 |
Cash Interest Paid | 0.53635 | 2.21944 | 2.91855 | 4.74485 | 0.42117 |
Changes in Working Capital | -19.1517 | -36.4816 | -129.134 | -177.604 | -59.8415 |
Cash From Investing Activities | 33.1924 | 292.728 | -850.081 | -831.01 | 115.187 |
Capital Expenditures | -0.82796 | -12.4208 | -17.0882 | -26.1562 | -1.1706 |
Other Investing Cash Flow Items, Total | 34.0204 | 305.149 | -832.993 | -804.854 | 116.358 |
Cash From Financing Activities | 11.0258 | 27.857 | 1317 | 1322.92 | 13.7736 |
Financing Cash Flow Items | 11.8149 | 29.2795 | 1234.36 | 1241.08 | 14.5762 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 84.7314 | 84.73 | |
Issuance (Retirement) of Debt, Net | -0.78905 | -1.42251 | -2.09185 | -2.88511 | -0.80261 |
Foreign Exchange Effects | -2.20631 | -1.45931 | -2.98555 | 2.98531 | 0.47603 |
Net Change in Cash | -0.20874 | 187.54 | 139.973 | 13.4536 | -14.3749 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 5.743 | 1965924 | 661108 | 2023-01-12 | LOW |
Armistice Capital LLC | Hedge Fund | 5.1648 | 1768000 | 732000 | 2023-01-10 | HIGH |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 4.7869 | 1638637 | -39276 | 2023-01-18 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 3.942 | 1349436 | -250322 | 2022-02-16 | MED |
RP Management, LLC | Private Equity | 3.9073 | 1337552 | 1337552 | 2021-07-29 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 3.6317 | 1243209 | 376568 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.2165 | 1101057 | -84879 | 2022-10-06 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 3.2134 | 1100000 | 1100000 | 2022-12-02 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 2.9531 | 1010913 | 10045 | 2021-09-20 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.819 | 965001 | 11213 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 2.4401 | 835292 | -1213122 | 2022-12-16 | LOW |
Morgan Stanley | Corporation | 1.5309 | 524062 | 524062 | 2022-11-21 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 1.3857 | 474360 | 0 | 2022-12-31 | LOW |
Bank of America Corp | Corporation | 1.2942 | 443038 | 128097 | 2022-12-22 | MED |
AMG Fondsverwaltung AG | Investment Advisor | 1.2112 | 414617 | 67321 | 2022-04-30 | LOW |
Eleva Capital SAS | Investment Advisor | 1.1824 | 404760 | 404760 | 2022-10-31 | HIGH |
Lupus alpha Asset Management AG | Investment Advisor/Hedge Fund | 1.1072 | 379000 | -52000 | 2022-10-31 | MED |
Mirova | Investment Advisor | 1.0159 | 347778 | -945 | 2022-11-30 | LOW |
Candriam Luxembourg S.A. | Investment Advisor | 0.9603 | 328727 | 0 | 2022-12-31 | HIGH |
Macquarie Investment Management | Investment Advisor | 0.8764 | 300000 | 0 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com GroupTraders
Clientes activos mensualmente
Volumen mensual de inversión
Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Morphosys Company profile
Sobre MorphoSys AG
MorphoSys AG desarrolla y comercializa anticuerpos para aplicaciones terapéuticas. La empresa desarrolla fármacos utilizando su propia investigación y desarrollo, así como en cooperación con socios farmacéuticos y biotecnológicos. Los segmentos operativos de la empresa incluyen el Desarrollo Propio y el Descubrimiento Asociado. En el segmento de Desarrollo Propio, desarrolla anticuerpos y péptidos terapéuticos en el ámbito de las enfermedades inflamatorias y la oncología. En el segmento Partnered Discovery, la empresa aplica tecnologías para la investigación, el desarrollo y la optimización de anticuerpos terapéuticos como candidatos a fármacos. La empresa desarrolla nuevos tratamientos para pacientes que padecen enfermedades graves. Sus tecnologías incluyen HuCAL, que es una colección de anticuerpos totalmente humanos y un sistema para su optimización; Ylanthia, que es una biblioteca de anticuerpos en formato Fab, y Slonomics, una tecnología automatizada de síntesis y modificación de genes para la generación de bibliotecas de genes en un proceso controlado.
Industry: | Biotechnology & Medical Research (NEC) |
Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 485.000 traders de todo el mundo que eligen operar con Capital.com